Metronidazole Immediate Release Formulations: A Fasting Randomized Open-Label Crossover Bioequivalence Study in Healthy Volunteers


Autoria(s): Silva, M. de Freitas; Schramm, S. G.; Kano, Eunice Kazue; Koono, E. E. M.; Manfio, J. L.; Porta, Valentina; Serra, Cristina Helena dos Reis
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Metronidazole is a BCS (Biopharmaceutics Classification System) class 1 drug, traditionally considered the choice drug in the infections treatment caused by protozoa and anaerobic microorganisms. This study aimed to evaluate bioequivalence between 2 different marketed 250 mg metronidazole immediate release tablets. A randomized, open-label, 2 x 2 crossover study was performed in healthy Brazilian volunteers under fasting conditions with a 7-day washout period. The formulations were administered as single oral dose and blood was sampled over 48 h. Metronidazole plasma concentrations were determined by a liquid chromatography mass spectrometry (LC-MS/MS) method. The plasma concentration vs. time profile was generated for each volunteer and the pharmacokinetic parameters C-max, T-max, AUC(0-t), AUC(0-infinity), k(e), and t(1/2) were calculated using a noncompartmental model. Bioequivalence between pharmaceutical formulations was determined by calculating 90% CIs (Confidence Intervall) for the ratios of C-max, AUC(0-t), and AUC(0-infinity) values for test and reference using log-transformed data. 22 healthy volunteers (11 men, 11 women; mean (SD) age, 28 (6.5) years [range, 21-45 years]; mean (SD) weight, 66 (9.3) kg [range, 51-81 kg]; mean (SD) height, 169 (6.5) cm [range, 156-186 cm]) were enrolled in and completed the study. The 90% CIs for C-max (0.92-1.06), AUC(0-t) (0.97-1.02), and AUC(0-infinity) (0.97-1.03) values for the test and reference products fitted in the interval of 0.80-1.25 proposed by most regulatory agencies, including the Brazilian agency ANVISA. No clinically significant adverse effects were reported. After pharmacokinetics analysis, it concluded that test 250 mg metronidazole formulation is bioequivalent to the reference product according to the Brazilian agency requirements.

CNPq

CNPq

FAPESP

FAPESP

FUNED

FUNED

FUNED (Fundacao Ezequiel Dias) (Belo Horizonte, Brazil)

FUNED (Fundacao Ezequiel Dias) (Belo Horizonte, Brazil)

Identificador

ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, STUTTGART, v. 62, n. 10, pp. 490-495, OCT, 2012

0004-4172

http://www.producao.usp.br/handle/BDPI/40937

10.1055/s-0032-1321873

http://dx.doi.org/10.1055/s-0032-1321873

Idioma(s)

eng

Publicador

GEORG THIEME VERLAG KG

STUTTGART

Relação

ARZNEIMITTELFORSCHUNG-DRUG RESEARCH

Direitos

restrictedAccess

Copyright GEORG THIEME VERLAG KG

Palavras-Chave #METRONIDAZOLE #HUMAN PLASMA #BIOEQUIVALENCE #BIOWAIVER #HPLC-MS/MS #HELICOBACTER-PYLORI INFECTION #HUMAN PLASMA #BIOAVAILABILITY #PHARMACOKINETICS #DISSOLUTION #CHEMISTRY, MEDICINAL #CHEMISTRY, MULTIDISCIPLINARY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion